Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Radius Health has successfully commercialized TYMLOS® (abaloparatide), a peptide analog of parathyroid hormone-related protein, approved by the FDA for osteoporosis treatment in postmenopausal women and men at high risk of fracture. The company also markets BINOSTO® (alendronate sodium) effervescent tablets for osteoporosis. Clinical results show TYMLOS increases bone density and reduces fracture risk, including patients unresponsive to other therapies[1][2][3].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Radius Pharmaceuticals.